Arrivent Biopharma Inc expected to post a loss of 66 cents a share - Earnings Preview

Reuters

May 05, 2025

Arrivent Biopharma Inc <avbp.oq> expected to post a loss of 66 cents a share - Earnings Preview </avbp.oq>

Arrivent Biopharma Inc AVBP.OQ AVBP.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Arrivent Biopharma Inc is for a loss of 66 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Arrivent Biopharma Inc is $39.00, above its last closing price of $21.30.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Dec. 31 2024	-0.78	-0.78	-0.61	Beat	21.5
Sep. 30 2024	-0.72	-1.00	-0.61	Beat	39.1
Jun. 30 2024	-0.65	-0.64	-0.65	Missed	-1
Mar. 31 2024	-1.09	-1.10	-0.70	Beat	36.2

This summary was machine generated May 5 at 11:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2533831725"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533831725\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533831725?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-05 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533831725","market":"nz","top_or_hot":-1,"title":"Arrivent Biopharma Inc  expected to post a loss of 66 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Arrivent Biopharma Inc <avbp.oq> expected to post a loss of 66 cents a share - Earnings Preview </avbp.oq></title></head><body><ul><li><p>Arrivent Biopharma Inc <span>AVBP.OQ</span> <span>AVBP.O</span> is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Arrivent Biopharma Inc is for a loss of 66 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Arrivent Biopharma Inc is $39.00, above its last closing price of $21.30. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-0.78</p></td><td><p>-0.78</p></td><td><p>-0.61</p></td><td><p>Beat</p></td><td><p>21.5</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-0.72</p></td><td><p>-1.00</p></td><td><p>-0.61</p></td><td><p>Beat</p></td><td><p>39.1</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-0.65</p></td><td><p>-0.64</p></td><td><p>-0.65</p></td><td><p>Missed</p></td><td><p>-1</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-1.09</p></td><td><p>-1.10</p></td><td><p>-0.70</p></td><td><p>Beat</p></td><td><p>36.2</p></td></tr><tr><td><p></p></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><p></p></td></tr></tbody></table><p>This summary was machine generated May 5 at 11:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arrivent Biopharma Inc  expected to post a loss of 66 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArrivent Biopharma Inc  expected to post a loss of 66 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-05 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Arrivent Biopharma Inc <avbp.oq> expected to post a loss of 66 cents a share - Earnings Preview </avbp.oq></title></head><body><ul><li><p>Arrivent Biopharma Inc <span>AVBP.OQ</span> <span>AVBP.O</span> is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Arrivent Biopharma Inc is for a loss of 66 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Arrivent Biopharma Inc is $39.00, above its last closing price of $21.30. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Dec. 31 2024</p></td><td><p>-0.78</p></td><td><p>-0.78</p></td><td><p>-0.61</p></td><td><p>Beat</p></td><td><p>21.5</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-0.72</p></td><td><p>-1.00</p></td><td><p>-0.61</p></td><td><p>Beat</p></td><td><p>39.1</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-0.65</p></td><td><p>-0.64</p></td><td><p>-0.65</p></td><td><p>Missed</p></td><td><p>-1</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-1.09</p></td><td><p>-1.10</p></td><td><p>-0.70</p></td><td><p>Beat</p></td><td><p>36.2</p></td></tr><tr><td><p></p></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td><p></p></td></tr></tbody></table><p>This summary was machine generated May 5 at 11:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVBP","symbol_name":"ArriVent BioPharma","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD0OF:1","article_id":"2533831725","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533831725","pubTimestamp":1746444791,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arrivent Biopharma Inc  expected to post a loss of66cents a share - Earnings Preview Arrivent Biopharma Inc AVBP.OQ AVBP.O is expected to show no change in quarterly revenue when it reports  results o","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AVBP":"ArriVent BioPharma"},"translate_title":"Arrivent Biopharma Inc预计每股亏损66美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVBP":0.9},"content_text":"Arrivent Biopharma Inc  expected to post a loss of 66 cents a share - Earnings Preview Arrivent Biopharma Inc AVBP.OQ AVBP.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025LSEG's mean analyst estimate for Arrivent Biopharma Inc is for a loss of 66 cents per share. The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Arrivent Biopharma Inc is $39.00, above its last closing price of $21.30. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Dec. 31 2024-0.78-0.78-0.61Beat21.5Sep. 30 2024-0.72-1.00-0.61Beat39.1Jun. 30 2024-0.65-0.64-0.65Missed-1Mar. 31 2024-1.09-1.10-0.70Beat36.2This summary was machine generated May 5 at 11:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}